Page 209 - HIV/AIDS Guidelines

Table 15e. Drug Interactions between Integrase Inhibitor and Other Drugs

Concomitant Drug Integrase Effect on Integrase Inhibitor or Concomitant Dosing Recommendations
Class/Name Inhibitor Drug Concentrations and Clinical Comments

Acid Reducers

Omeprazole RAL RAL AUC ↑ 212%, C max ↑ 315%, and C min ↑ 46% No dosage adjustment necessary.
Antimycobacterials

Rifabutin RAL RAL AUC ↑ 19%, C max ↑ 39%, and C min ↓ 20% No dosage adjustment necessary.
Rifampin RAL RAL 400 mg: RAL AUC ↓ 40% and C min ↓ 61% Dose: RAL 800 mg BID
Rifampin with RAL 800 mg BID compared with RAL Monitor closely for virologic
400 mg BID alone: RAL AUC ↑ 27% and response.
C min ↓ 53%
Hepatitis C NS3/4A – Protease Inhibitors
Boceprevir RAL No significant effect No dosage adjustment necessary.

Telaprevir RAL RAL AUC ↑ 31% No dosage adjustment necessary.
Telaprevir ↔

Hormonal Contraceptives
Hormonal contraceptives RAL No clinically significant effect Safe to use in combination
Narcotics/Treatment for Opioid Dependence

Buprenorphine RAL No significant effect No dosage adjustment necessary.
Methadone RAL No significant effect No dosage adjustment necessary.

Key to Abbreviations: AUC = area under the curve, BID = twice daily, C max = maximum plasma concentration, C min = minimum plasma
concentration, RAL = raltegravir

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents K-39

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.